Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
SNSE Sensei Biotherapeutics Inc
ALGS Aligos Therapeutics Inc
SRRA Sierra Oncology Inc
ATOS Atossa Therapeutics Inc
OSMT Osmotica Pharmaceuticals PLC
SAND Sandstorm Gold Ltd
GRVI Grove Inc
STON Stonemor Inc
TK Teekay Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium. KarXT combines xanomeline, a muscarinic agonist, with trospium, a muscarinic antagonist, to stimulate muscarinic receptors in the CNS. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms.

Price
Delayed
$124.67
Day's Change
0.055 (0.04%)
Bid
--
Ask
--
B/A Size
--
Day's High
125.49
Day's Low
121.22
Volume
(Light)

Today's volume of 22,044 shares is on pace to be much lighter than KRTX's 10-day average volume of 191,081 shares.

22,044

JPMorgan Chase Reports Third-Quarter 2021 Financial Results

6:52 am ET October 13, 2021 (BusinessWire) Print

JPMorgan Chase & Co. has released its third-quarter 2021 financial results. Results can be found at the Firm's Investor Relations website at jpmorganchase.com/ir/quarterly-earnings.

JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorgan Chase had $3.8 trillion in assets and $290.0 billion in stockholders' equity as of September 30, 2021. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world's most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005584/en/

SOURCE: JPMorgan Chase & Co.

Investor Contact:
Reggie Chambers
212-270-2479

Media Contact:
Trish Wexler
212-270-5883
comtex tracking

COMTEX_395094180/1006/2021-10-13T06:52:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.